Browsing by Author "Masana, Luís"

Sort by: Order: Results:

  • Effect of statin therapy on SARS-CoV-2 infection-related
    Masana, Luís; Correig, Eudald; Rodríguez-Borjabad, Cèlia; Anoro, Eva; Arroyo-Díaz, Juan Antonio; Jericó, Carlos; Pedragosa, Angels; Miret, Marcel·la; Näf, Silvia; Pardo, Anna; Perea, Verónica; Pérez-Bernalte, Rosa; Plana, Nuria; Ramírez-Montesinos, Rafael; Royuela, Meritxell; Soler, Cristina; Urquizu-Padilla, Maria; Masana, Luís; Pedro-Botet, Juan Carlos; The Stacov-Xula Research Group (Oxford University Press, 2022)
    Aim: Assessing the effect of statin therapy at hospital admission for COVID-19 on in-hospital mortality. Methods and results: Retrospective observational study. Patients taking statins were 11 years older and had significantly ...
  • Familial hypercholesterolemia in a European Mediterranean population-Prevalence and clinical data from 2.5 million primary care patients
    Zamora, Alberto; Masana, Luís; Comas Cufí, Marc; Vila, Alex; Plana, Nuria; Garcıa-Gil, Maria; Alves-Cabratosa, Lia; Marrugat de la Iglesia, Jaume; Roman Degano, Irene; Ramos, Rafel; XULA and ISV-Girona groups (Elsevier, 2017)
    BACKGROUND: Familial hypercholesterolemia (FH), the most frequent hereditary cause of premature coronary heart disease (CHD), is underdiagnosed and insufficiently treated. OBJECTIVES: The objectives of the study were to ...
  • Incidence of cardiovascular disease in patients with familial hypercholesterolemia phenotype: analysis of 5 years follow-up of real-world data from more than 1.5 million patients
    Masana, Luís; Zamora, Alberto; Plana, Nuria; Comas Cufí, Marc; Garcıa-Gil, Maria; Martí, Ruth; Ponjoan, Anna; Alves-Cabratosa, Lia; Elosua Llanos, Roberto; Marrugat de la Iglesia, Jaume; Dégano, Irene R.; Ramos, Rafel (MDPI, 2019)
    In the statin era, the incidence of atherosclerotic cardiovascular diseases (ASCVD) in patients with familial hypercholesterolemia (FH) has not been updated. We aimed to determine the incidence of ASCVD in patients with ...
  • Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019
    Ascaso Gimilio, Juan Francisco; Civeira, Fernando; Guijarro, Carlos; López Miranda, José; Masana, Luís; Mostaza, José María; Pedro-Botet, Juan Carlos; Pintó Sala, Xavier; Valdivielso, Pedro (Elsevier, 2019)
    A group of experts convened by the Spanish Society of Arteriosclerosis (SEA) has been in charge of updating the SEA document on the indications of PCSK9 inhibitors (PCSK9i) in clinical practice that was published in 2016. ...
  • Low HDL and high triglycerides predict COVID-19 severity
    Masana, Luís; Correig, Eudald; Ibarretxe, Daiana; Anoro, Eva; Arroyo-Díaz, Juan Antonio; Jericó, Carlos; Guerrero, Carolina; Miret, Marcel·la; Näf, Silvia; Pardo, Anna; Perea, Verónica; Pérez-Bernalte, Rosa; Plana, Nuria; Ramírez-Montesinos, Rafael; Royuela, Meritxell; Soler, Cristina; Urquizu-Padilla, Maria; Zamora, Alberto; Pedro-Botet, Juan Carlos; The Stacov-Xula Research Group (Nature Research, 2021)
    Lipids are indispensable in the SARS-CoV-2 infection process. The clinical significance of plasma lipid profile during COVID-19 has not been rigorously evaluated. We aim to ascertain the association of the plasma lipid ...
  • PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk
    Rehues, Pere; Girona, Josefa; Guardiola, Montse; Plana, Nuria; Scicali, Roberto; Piro, Salvatore; Muñiz-Grijalvo, Ovidio; Díaz Díaz, José Luis; Recasens, Lluís; Pinyol, Marta; Rosales, Roser; Esteban, Yaiza; Amigó, Núria; Masana, Luís; Ibarretxe, Daiana; Ribalta, Josep (MDPI, 2023)
    Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol ...
  • Situación en 2020 de los requerimientos para la utilización de inhibidores de PCSK9 en España: resultados de una encuesta nacional
    Guijarro, Carlos; Civeira, Fernando; López Miranda, José; Masana, Luís; Pedro-Botet, Juan Carlos; Pintó Sala, Xavier; Valdivielso, Pedro; Mostaza, José María (Elsevier, 2022)
    Aims: During 2019 and 2020 a series of meetings over the country were carried out, with the aim of explaining the methodology and criteria for the ellaboration of the recommendations on the use of iPCSK9, published by the ...
  • Women with familial hypercholesterolemia phenotype are undertreated and poorly controlled compared to men
    Zamora, Alberto; Ramos, Rafel; Comas Cufí, Marc; García Gil, Maria; Martí-Lluch, Ruth; Plana, Nuria; Alves-Cabratosa, Lia; Ponjoan, Anna; Rodríguez-Borjabad, Cèlia; Ibarretxe, Daiana; Roman Degano, Irene; Marrugat de la Iglesia, Jaume; Elosua Llanos, Roberto; Martin-Urda Diez-Canseco, Anabel; Masana, Luís (Nature Research, 2023)
    Familial hypercholesterolemia (FH) is an autosomal dominant disease that has a prevalence of approximately 1/250 inhabitants and is the most frequent cause of early coronary heart disease (CHD). We included 1.343.973 women ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking